Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q3 FY2022 Earnings Presentation
51 slides from Jubilant Ingrevia's earnings presentation, Feb 1, 2022
Slide 1: Jubilant Ingrevia – Q3 & 9M'FY22 Results
Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantingrevia.com Noida, Tuesday, February 01, 2022 JUBILANT INGREVIA – Q3 & 9M’FY22 RESULTS* (Rs Crs) Particulars1 Q3'FY212 Q3'FY22 YoY (%) 9M'FY212 9M'FY22 YoY (%) Total Revenue from Operatio
Slide 2: Q3'FY22 Highlights
Q3’FY22 Highlights A. Consolidated Particulars1 Q3'FY212 Q3'FY22 YoY (%) Revenue Speciality Chemicals 285 349 22% Nutrition & Health Solutions 157 216 37% Life Science Chemicals 451 722 60% Total Revenue from Operations 893 1,286 44% Reported EBITDA 157 222 42% Speciality Chemicals 59 76 28% Nutriti
Slide 3: Nutrition & Health Solutions; Life Science Chemicals Segment
C. Nutrition & Health Solutions Particulars1 Q3'FY212 Q3'FY22 YoY (%) Revenue 157 216 37% Reported EBITDA 28 53 87% Reported EBITDA Margin (%) 17.9% 24.4% Nutrition and Health Solutions revenue grew by 37% on YoY basis. Growth of Vitamin Business was driven by higher volumes and improved prices.
Slide 4: Nine Months'FY22 Highlights
Nine Months’FY22 Highlights E. Consolidated Particulars1 9M'FY212 9M'FY22 YoY (%) Revenue Speciality Chemicals 794 949 19% Nutrition & Health Solutions 431 562 30% Life Science Chemicals 1,189 2,143 80% Total Revenue from Operations 2,413 3,654 51% Reported EBITDA 424 712 68% Speciality Chemicals 19
Slide 5: Nutrition & Health, Life Science Chemicals, Business Outlook
G. Nutrition & Health Solutions Particulars1 9M'FY212 9M'FY22 YoY (%) Revenue 431 562 30% Reported EBITDA 88 114 30% Reported EBITDA Margin (%) 20.4% 20.3% Nutrition and Health Solutions revenue grew by 30% on YoY basis. Growth of Vitamin Business was driven by higher volumes and improved prices
Slide 6: Debt Position and Balance Sheet Key Parameters
J. Debt Position – As on 31st December, 2021 Particulars1 31-Mar-21 30-Jun-21 30-Sep-21 31-Dec-21 Long Term Borrowings 548 227 218 100 Short Term Borrowings - 230 45 184 Total Gross Debt 548 457 263 284 Cash & Equivalent 117 70 70 54 Total Net Debt 431 386 193 230 QoQ change -10% -50% 19% Gross De
Slide 7: Income Statement – Q3 & Nine Months'FY22
L. Income Statement – Q3 & Nine Months’FY22 Particulars1 Q3'FY212 Q3'FY22 YoY (%) 9M'FY212 9M'FY22 YoY (%) Total Revenue from Operations 893 1,286 44% 2,413 3,654 51% Speciality Chemicals 285 349 22% 794 949 19% Nutrition & Health Solutions 157 216 37% 431 562 30% Life Science Chemicals 451 722 60%
Slide 8: About Jubilant Ingrevia Limited
About Jubilant Ingrevia Limited Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and c
Slide 9: Disclaimer
Disclaimer: Note 1 Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target
Slide 10: Investor Presentation
Investor Presentation February 2022
Slide 11: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 12: Company Overview
Company Overview
Slide 13: Jubilant Bhartia Group - Snapshot
Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Prod
Slide 14: Business Segments & Integrated Operations
Business Segments & Integrated Operations Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customized products and solutions Integrated Operations… Vertical
Slide 15: Glorious Four Decades of Growth
Glorious Four Decades of Growth Our Journey 10+ years experience in 2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA) 2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ Vitamin B3 Demerger into 2017: Certified for Responsible Care (RC) 2021 new entity 2015: Commissioned sp
Slide 16: Company Snapshot
Company Snapshot Leadership Revenue Segmentation: By Region (9M FY’22) Total 1400+ customers - Globally # 1 in 14 Pyridine Derivatives • Speciality Chemicals: 420 - Amongst top 2 Globally in (Pyridine + Beta) N.America RoW Domestic Sales • Nutrition & Health Solutions: 400 5% 9% for International •
Slide 17: Executive Leadership Team
Executive Leadership Team Rajesh Srivastava Chief Executive Officer & Managing Director 34 years of industry experience Anil Khubchandani Chandan Singh Sumit Das Ashish Kumar Sinha President – President – SVP – Nutrition & VP – Animal & Human Speciality Chemicals Life Science Chemicals Health Ingred
Slide 18: Multi Location Manufacturing & Operation Excellence
Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India Nira, Maharashtra, India Samlaya, Gujarat, India Ambernath, Maharashtra, India Speciality Chemicals, Life Science Chemicals
Slide 19: Research Development & Technology (RDT)
Research Development & Technology (RDT) 3 RDT centers in Noida, Gajraula and Bharuch 35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Key Grignard etc. Highlights 90 highly qualified scientists (~20 PhDs) 60+ Products in Pipeline for next 5 y
Slide 20: End Usage Applications for Pharma, Agrochemicals & Nutraceuticals
End Usage Applications for Pharma, Agrochemicals & Nutraceuticals Therapeutic Category Our Product Category (GMP & Non-GMP) (Used in ~ 53 APIs) Pyridine, Picolines Amino Methyl Chloro/ Bromo/ Pyridines Fluoro Pyridines Antipyretic Analgesic Antifibrosis Off- Patented Amino Pyridines Hydroxy Methyl P
Slide 21: Industry Overview: Presence in Large & Growing Markets
Industry Overview: Presence in Large & Growing Markets1 Global Speciality Chemicals Global API Market CAGR 6.4% CAGR 5.8% $ 910 Bn $ 1240 Bn $ 197 Bn $ 262 Bn Speciality FY'21 FY 26 P FY'21 FY'26 P Chemicals Indian Speciality Chemicals Indian API Market CAGR 12.4% CAGR 7.9% $ 41 Bn $ 72 Bn $ 4 Bn $
Slide 22: Financial Highlights: Q3 FY'22 & 9M FY'22
Financial Highlights: Q3 FY’22 & 9M FY’22
Slide 23: Chairmen's Message on Q3 Financial Results
Chairmen’s Message on Q3 Financial Results Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are pleased to announce that in Q3’FY22 we continued to witness significant growth in our Revenue & EBITDA. We are also delighted to declared an interim dividend of Rs. 2.5 per equity share of
Slide 24: Financial Highlights: Key Financial Parameters
Financial Highlights1 : Key Financial Parameters Highlights ₹ 1,286 Cr. ₹ 222 Cr. 17.3% ₹ 129 Cr. 10.0% ₹ 8.1 Q3’FY22 Sales EBITDA EBITDA (%) PAT PAT (%) EPS 44% YoY 42% YoY (29) bps 42% YoY (15) bps 42% YoY Highlights ₹ 893 Cr. ₹ 157 Cr. 17.5% ₹ 91 Cr. 10.2% ₹ 5.7 Q3’FY21 2 Sales EBITDA EBITDA (%)
Slide 25: Q3 FY'22 Financial Results Summary
Jubilant Ingrevia – Q3 FY’22 Financial Results Summary Particulars1 Q3'FY212 Q3'FY22 YoY (%) Revenue FINANCIAL HIGHLIGHTS Speciality Chemicals 285 349 22% • Revenue grew by 44% on YoY basis, driven by growth across Nutrition & Health Solutions 157 216 37% product segments. Life Science Chemicals 451
Slide 26: 9M FY'22 Financial Results Summary
Jubilant Ingrevia – 9M FY’22 Financial Results Summary Particulars1 9M'FY212 9M'FY22 YoY (%) Revenue FINANCIAL HIGHLIGHTS Speciality Chemicals 794 949 19% • Revenue grew by 51% on YoY basis, driven by growth across Nutrition & Health Solutions 431 562 30% product segments. Life Science Chemicals 1,1
Slide 27: Debt Profile – As on 31st December, 2021
Debt Profile – As on 31st December, 2021 Particulars1 31-Mar-21 30-Jun-21 30-Sep-21 31-Dec-21 Long Term Borrowings 548 227 218 100 Short Term Borrowings - 230 45 184 Total Gross Debt 548 457 263 284 Cash & Equivalent 117 70 70 54 Total Net Debt 431 386 193 230 QoQ change -10% -50% 19% Gross Debt r
Slide 28: Balance Sheet – Key Parameters/Ratios
Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) Return on Equity Asset / Turnover and Return On Asset (RoA) 2.0x 2.8x 25.2% 31.1% 15.3% 20.2% 9.4% (%age) (%age) (%age) 16.4% FY'21 9M'FY22 FY'21 9M'FY22 FY'21 9M'FY22 FY'21 9M'FY22 FY'21 9M'FY22 Asset / Turnover FY
Slide 29: Business Segments Overview
BUSINESS SEGMENTS OVERVIEW
Slide 30: Speciality Chemicals – Segment Snapshot
Speciality Chemicals – Segment Snapshot Geographical Revenue Split (9M FY’22) FY’21 Capacity Utilisation: 74% 85 Products Amongst top 2 (Pyridines & Globally lowest Domestic Sales Capacity Growth in FY’22 Capacity Growth in FY’23 Globally in for International Picolines, cost producer of over FY’21:
Slide 31: Speciality Chemicals Segment Highlights – Q3 FY'22
Speciality Chemicals Segment Highlights – Q3 FY’22 FINANCIAL HIGHLIGHTS Particulars1 Q3'FY212 Q3'FY22 YoY (%) Revenue 285 349 22% Specialty Chemicals revenue grew by 22% on YoY basis driven Reported EBITDA 59 76 28% by higher volume across product segments Reported EBITDA Margin (%) 20.8% 21.8%
Slide 32: Speciality Chemicals Segment Highlights – 9M FY'22
Speciality Chemicals Segment Highlights – 9M FY’22 Particulars1 9M'FY212 9M'FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 794 949 19% Specialty Chemicals revenue grew by 19% on YoY Reported EBITDA 199 231 16% basis driven by higher volume across product. Reported EBITDA Margin (%) 25.1% 24.4% Domest
Slide 33: Nutrition & Health Solutions – Segment Snapshot
Nutrition & Health Solutions – Segment Snapshot Revenue Segmentation (9M FY’22) FY’21 Capacity Utilisation: 70% 5 Nutrition 100% in-house Global top 2 in By Region Ingredients & sourcing of Beta By End use Capacity growth in FY’22 Capacity growth in FY’23 Vitamin B3 Domestic Sales for 18+ branded Pi
Slide 34: Nutrition & Health Solutions Segment Highlights – Q3 FY'22
Nutrition & Health Solutions Segment Highlights – Q3 FY’22 FINANCIAL HIGHLIGHTS Particulars1 Q3'FY212 Q3'FY22 YoY (%) Nutrition and Health Solutions revenue grew by 37% on YoY basis. Revenue 157 216 37% Growth of Vitamin Business was driven by higher volumes and improved prices . Reported EBITDA
Slide 35: Nutrition & Health Solutions Segment Highlights – 9M FY'22
Nutrition & Health Solutions Segment Highlights – 9M FY’22 Particulars1 9M'FY212 9M'FY22 YoY (%) FINANCIAL HIGHLIGHTS Revenue 431 562 30% Reported EBITDA 88 114 30% Nutrition and Health Solutions revenue grew by 30% Reported EBITDA Margin (%) 20.4% 20.3% on YoY basis. • Growth of Vitamin Business
Slide 36: Life Sciences Chemicals – Segment Snapshot
Life Sciences Chemicals – Segment Snapshot Acetic Anhydride: Region wise Revenue Segmentation FY’21 Capacity Utilisation: 69% Entered Value added 8 Products Globally No. 2 in derivative Propionic For Segment (9M FY’22) Domestic Sales for (Acetic Anhydride, Capacity growth in FY’22 Capacity growth in
Slide 37: Life Science Chemicals Segment Highlights – Q3 FY'22
Life Science Chemicals Segment Highlights – Q3 FY’22 FINANCIAL HIGHLIGHTS 1 2 Particulars Q3'FY21 Q3'FY22 YoY (%) Life Sciences Chemicals revenue grew by 60% on YoY basis Revenue 451 722 60% • Life Sciences Chemical revenue growth was driven by higher Reported EBITDA 68 100 48% prices of Ethyl Ace
Slide 38: Life Science Chemicals Segment Highlights – 9M FY'22
Life Science Chemicals Segment Highlights – 9M FY’22 FINANCIAL HIGHLIGHTS Particulars1 9M'FY212 9M'FY22 YoY (%) Revenue 1,189 2,143 80% Life Sciences Chemicals revenue grew by 80% on Reported EBITDA 131 387 195% YoY basis Reported EBITDA Margin (%) 11.0% 18.1% • Life Sciences Chemical revenue grow
Slide 39: Future Outlook & Investments
Future Outlook & Investments
Slide 40: Business outlook
Business outlook We expect demand of most of our Products to remain strong. Our Diketene plant is under commissioning now, and we expect to start our commercial production during the current quarter. Our committed investment worth Rs. 450 Crore for key growth capex is progressing well . At pea
Slide 41: Overall Expansion Plan
Overall Expansion Plan: Jubilant Ingrevia JVL: Jubilant Ingrevia Limited Plan to double the Revenue by FY’26 from the base of FY’21. Key Projects Capacity Build Up for Growth starting during next 3 years (Quarter in which production is starting) Available Capacity & Expansion Plan (CAGR: 8.3%) 90% 9
Slide 42: Rationale for Investment
Rationale for Investment Proposed Investment Rationale for Investment New facility for launch of 6 Diketene derivatives. Subsequently, Forward integration of our Ketene capability and growing demand of add 8 value-added Diketene derivatives Diketene derivatives globally as well as Import replacement
Slide 43: Quality, Business Excellence, Sustainability
BUSINESS QUALITY SUSTAINABILITY EXCELLENCE
Slide 44: Jubilant Ingrevia: Global Accreditation
Jubilant Ingrevia: Global Accreditation Select Certifications Gajraula Bharuch Nira Samlaya Ambernath Responsible Care RC 14001:2015 ISO 9001:2015 ISO 22000:2005 ISO 14001:2015 ISO 45001:2018 FSSAI FAMI-QS HALAL KOSHER GMP State State FDA G
Slide 45: Business Excellence and Digital Transformation
Business Excellence and Digital Transformation Belt Competencies (FY’21) Digital Transformation Black Belts: 08 Green Belts: 98 Yellow Belts: 141 Our journey started in 2018 with an objective to improve Business Excellence Operational efficiency Tools & Processes Business & Supply chain proces
Slide 46: CSR - Jubilant Bhartia Foundation
CSR - Jubilant Bhartia Foundation Mission: To develop multi-stakeholder sustainable models to bring about Established ‘social change’ involving knowledge generation & sharing, experiential in 2007 learning & entrepreneurial ecosystem *A sister organization of World Economic Forum*in Partnership with
Slide 47: Sustainability Journey
Sustainability Journey Our Sustainability Journey SDG: Key Achievements ESG Assessment Responsible care policy First Product 37% Reduction in Specific Water Life Cycle 2014 Consumption wrt FY’13 UNGC Assessment Signatory & Climate Change Participation 2012 27% Reduction in Specific Mitigation & in C
Slide 48: Our Vision, Values, Promise and Philosophy
Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing
Slide 49: For More Information
For More Information For Investors: Siddharth Rangnekar CDR India Pavleen Taneja Ph: +91 22 6645 1209 Ph: +91 120 436 1021 E-mail: siddharth@cdr-india.com E-mail: pavleen.taneja@jubl.com For Media: Clayton Dsouza Sudhakar Safaya Madison Public Relations Ph: +91 120 436 1034 E-mail: clayton.dsouza@ma
Slide 50: Appendix I: Income Statement – Q3 & 9M FY'22
Appendix I: Income Statement – Q3 & 9M FY’22 Particulars1 Q3'FY212 Q3'FY22 YoY (%) 9M'FY212 9M'FY22 YoY (%) Total Revenue from Operations 893 1,286 44% 2,413 3,654 51% Speciality Chemicals 285 349 22% 794 949 19% Nutrition & Health Solutions 157 216 37% 431 562 30% Life Science Chemicals 451 722 60%
Slide 51: Appendix II - Conference Call Details
Appendix II - Conference Call Details Date : February 01, 2022 Time : 05:00 pm IST Conference Dial-In Numbers + 91 22 6280 1141 Universal Access: + 91 22 7115 8042 USA: 1 866 746 2133 Toll Free Number: UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 Available from October 19 to Oct